Dr. Erica L. Mayer, MD MPH
Claim this profileDana-Farber Cancer Institute
Studies Breast Cancer
Studies BRCA1 Mutation
8 reported clinical trials
19 drugs studied
Area of expertise
1Breast Cancer
Stage II
HER2 negative
Stage III
2BRCA1 Mutation
HER2 negative
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Erica L. Mayer, MD MPH is currently running
Enzalutamide + Mifepristone or Chemotherapy
for Breast Cancer
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Recruiting1 award Phase 218 criteria
Avelumab Combinations
for Triple Negative Breast Cancer
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
Recruiting1 award Phase 211 criteria
More about Erica L. Mayer, MD MPH
Clinical Trial Related4 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Erica L. Mayer, MD MPH has experience with
- Palbociclib
- Avelumab
- Exemestane
- Standard Adjuvant Endocrine Therapy
- Abemaciclib
- Anastrozole/Letrozole
Breakdown of trials Erica L. Mayer, MD MPH has run
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
PALB2 Mutation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Erica L. Mayer, MD MPH specialize in?
Erica L. Mayer, MD MPH focuses on Breast Cancer and BRCA1 Mutation. In particular, much of their work with Breast Cancer has involved Stage II patients, or patients who are HER2 negative.
Is Erica L. Mayer, MD MPH currently recruiting for clinical trials?
Yes, Erica L. Mayer, MD MPH is currently recruiting for 3 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Erica L. Mayer, MD MPH has studied deeply?
Yes, Erica L. Mayer, MD MPH has studied treatments such as Palbociclib, Avelumab, Exemestane.
What is the best way to schedule an appointment with Erica L. Mayer, MD MPH?
Apply for one of the trials that Erica L. Mayer, MD MPH is conducting.
What is the office address of Erica L. Mayer, MD MPH?
The office of Erica L. Mayer, MD MPH is located at: Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana-Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.